Covea Finance’s Edwards Lifesciences EW Stock Holding History

Covea Finance’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.34M	Hold	81,101	–	–	0.23%	94
2026 Q1	$6.49M	Hold	81,101	–	–	0.23%	94
2025 Q4	$6.91M	Hold	81,101	–	–	0.23%	91
2025 Q3	$6.31M	Buy	+81,101	New	+$6.34M	0.22%	90

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Covea Finance's EW Position: Q2 2026 in Review

Covea Finance held its Edwards Lifesciences (EW) position steady in Q2 2026 at 81,101 shares worth $7.34M. The position accounts for 0.23% of the portfolio, ranked #94.

Covea Finance first reported a position in EW in Q3 2025 and has held it in 4 quarters since. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Covea Finance held 81,101 shares of Edwards Lifesciences worth $7.34M as of Q2 2026.
Covea Finance left its Edwards Lifesciences share count unchanged in Q2 2026.
Edwards Lifesciences made up 0.23% of Covea Finance's portfolio in Q2 2026, its #94 holding.
Covea Finance first reported a position in Edwards Lifesciences in Q3 2025 and has held it in 4 quarters since.
1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Covea Finance's 13F filing for Q2 2026, filed 13 Jul 2026.